AC Immune SA (ACIU)

Price$2.25

Value ScoreC

Growth ScoreD

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-32.67%

Price vs S&P 500 (4W)-21.32%

VGM Score41.61

Market Capitalization$287.23M

All Metrics

P/CF (Annual)3.38x

Book Value / Share (Quarterly)$0.39

P/TBV (Annual)3.40x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-2.88%

Cash Flow / Share (Quarterly)$-0.87

Price vs S&P 500 (YTD)-36.50%

Net Profit Margin (TTM)-1788.79%

EPS (TTM)$-0.83

10-Day Avg Trading Volume0.28M

EPS Excl Extra (TTM)$-0.83

Revenue Growth (5Y)-25.34%

EPS (Annual)$-0.88

ROI (Annual)-142.53%

Net Profit Margin (5Y Avg)-948.37%

Cash / Share (Quarterly)$0.93

Revenue Growth QoQ (YoY)13.03%

ROA (Last FY)-45.67%

Revenue Growth TTM (YoY)-86.92%

EBITD / Share (TTM)$-0.84

ROE (5Y Avg)-61.88%

Operating Margin (TTM)-1748.68%

Cash Flow / Share (Annual)$-0.87

P/B Ratio5.69x

P/B Ratio (Quarterly)6.99x

Net Income / Employee (Annual)$-727,522

EV / Revenue (TTM)44.49x

Net Interest Coverage (TTM)-61.40x

ROA (TTM)-40.53%

EV / EBITDA (TTM)3.56x

EPS Incl Extra (Annual)$-0.88

Current Ratio (Annual)1.02x

Quick Ratio (Quarterly)0.83x

3-Month Avg Trading Volume0.28M

52-Week Price Return30.06%

EV / Free Cash Flow (Annual)3.05x

Revenue / Employee (TTM)$38,178

Tangible BV / Share (Quarterly)$0.15

P/S Ratio (Annual)50.26x

Asset Turnover (Annual)0.02x

52-Week High$4.00

Operating Margin (5Y Avg)-941.52%

EPS Excl Extra (Annual)$-0.88

CapEx CAGR (5Y)-12.05%

Tangible BV CAGR (5Y)0.30%

26-Week Price Return-24.75%

Quick Ratio (Annual)0.98x

13-Week Price Return-17.58%

Total Debt / Equity (Annual)0.10x

Current Ratio (Quarterly)0.87x

Enterprise Value$207.52M

Revenue / Share Growth (5Y)-30.20%

Asset Turnover (TTM)0.02x

Book Value / Share Growth (5Y)-31.83%

Revenue / Employee (Annual)$36,918

Pretax Margin (Annual)-1971.65%

Cash / Share (Annual)$1.13

3-Month Return Std Dev63.15%

Net Income / Employee (TTM)$-683,926

ROE (Last FY)-156.95%

Net Interest Coverage (Annual)-18.84x

EPS Basic Excl Extra (Annual)$-0.88

P/FCF (TTM)2.26x

Receivables Turnover (TTM)6.41x

Total Debt / Equity (Quarterly)0.14x

EPS Incl Extra (TTM)$-0.83

Receivables Turnover (Annual)4.90x

ROI (TTM)-114.16%

P/S Ratio (TTM)48.51x

Pretax Margin (5Y Avg)-947.84%

Revenue / Share (Annual)$0.04

Tangible BV / Share (Annual)$0.78

Free OCF CAGR (5Y)4.12%

Price vs S&P 500 (52W)5.69%

Year-to-Date Return-28.34%

5-Day Price Return-8.54%

EPS Normalized (Annual)$-0.88

ROA (5Y Avg)-32.68%

Net Profit Margin (Annual)-1971.65%

Month-to-Date Return-15.41%

Cash Flow / Share (TTM)$-0.87

EBITD / Share (Annual)$-0.84

Operating Margin (Annual)-1940.05%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-58.22%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.83

P/TBV (Quarterly)19.00x

P/B Ratio (Annual)5.45x

Pretax Margin (TTM)-1788.79%

Book Value / Share (Annual)$0.56

Price vs S&P 500 (13W)-25.84%

Beta1.59x

P/FCF (Annual)2.75x

Revenue / Share (TTM)$0.05

ROE (TTM)-124.01%

52-Week Low$1.65

vGradeC

gGradeD

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.19est. -0.20

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.40

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
ACIUAC Immune SA	C	D	C	$2.25
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

AC Immune SA is a clinical-stage biopharmaceutical company focused on neurodegenerative diseases caused by protein misfolding. The company uses proprietary technology platforms to develop small molecules, antibodies, and vaccines for both therapeutic and diagnostic applications. Its pipeline includes clinical-stage candidates such as Crenezumab and Semorinemab.